An antisense drug is a short sequence of RNA which hybridises with and inactivates mRNA, preventing the protein from being formed.

[citation needed] It was shown that the proliferation of human lymphoma cells (with t(14;18) translocation) could be inhibited by antisense RNA targeted at the start codon region of Bcl-2 mRNA.

[2] By the first quarter 2010, the drug had not received FDA approval due to disappointing results in a melanoma trial.

Preclinical models have demonstrated that oblimersen, when combined with vinorelbine, significantly inhibits tumor growth and prolongs survival in NSCLC.

These findings suggest that combining oblimersen with other chemotherapeutic agents could enhance its efficacy and potentially overcome previous clinical challenges.